开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 05-22 16:08:21

2.630

-0.010

-0.38%

最高2.680	最低2.570	成交量102.70万
今开2.650	昨收2.640	日振幅4.17%
总市值13.12亿	流通市值13.12亿	总股本4.99亿
成交额266.93万	换手率0.21%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.63,"timestamp":1779437301097,"preClose":2.64,"halted":0,"volume":1027000,"delay":0,"changeRate":-0.003787878787878875,"floatShares":499000000,"shares":499000000,"eps":-0.5129730865296463,"marketStatus":"休市中","change":-0.01,"latestTime":"05-22 16:08:21","open":2.65,"high":2.68,"low":2.57,"amount":2669330,"amplitude":0.041667,"askPrice":2.7,"askSize":30000,"bidPrice":2.63,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.5119284757210802,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779759000000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.64,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":0.84708,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2637310625","title":"新股消息 | 勤浩医药拟港股上市 中国证监会要求补充说明近三年净资产数据等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310625","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637310625?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:52","pubTimestamp":1779457966,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月22日，中国证监会公布境外发行上市备案补充材料要求公示。中国证监会国际司共对17家企业出具补充材料要求，其中，要求勤浩医药补充公司近三年净资产、净利润数据等事项。据悉，勤浩医药已于2026年1月16日递表港交所，华泰国际为独家保荐人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IPOS","159938","09939","VXUS","BK1161","BK1515","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317411","title":"复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637317411?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:51","pubTimestamp":1779457861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主开发的斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见，推荐批准斯鲁利单抗联合卡铂和白蛋白紫杉醇适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。一旦获得EC批准，斯鲁利单抗的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于一项随机、双盲、国际多中心3期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","HK0000320223.HKD","BK1515","02696","HK0000165453.HKD","HK0000306685.HKD","159938","09939","HK0000306701.USD","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138573","title":"森萱医药（920946）披露关于注销募集资金专户的公告，5月22日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138573?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:00","pubTimestamp":1779444054,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，森萱医药报收于9.64元，较前一交易日下跌0.52%，最新总市值为41.15亿元。该股当日开盘9.81元，最高9.81元，最低9.57元，成交额达1962.52万元，换手率为0.48%。近日，森萱医药发布《关于注销募集资金专户的公告》。相关《募集资金专户三方监管协议》随之终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637909390","title":"白云山(00874)：广州医药完成10亿元应收账款资产证券化","url":"https://stock-news.laohu8.com/highlight/detail?id=2637909390","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637909390?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:29","pubTimestamp":1779442189,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山 发布公告，于2026年4月27日，广州医药与兴证资管签订《兴业圆融-广州医药应收账款5期资产支持专项计划基础资产买卖协议》，发行规模为人民币10亿元。据此，广州医药于2026年5月22日与兴证资管签订《交割确认函》，确认向兴证资管出售初始基础资产，并收到购买价款人民币10亿元。广州医药为本公司的一家于中国成立的非全资附属公司，由本公司拥有90.92%股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK1191","BK1197","BK1606","BK0097","BK1574","BK0096","00874","BK0196","BK0028","BK0239","BK0012","BK0175","BK0183","BK1515","BK1521","BK1161","09939","159938","BK0188","600332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637433604","title":"青海湟中全域推广中（藏）医药康养文化 让传统医药可触可享","url":"https://stock-news.laohu8.com/highlight/detail?id=2637433604","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637433604?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:42","pubTimestamp":1779367320,"startTime":"0","endTime":"0","summary":"中新网西宁5月21日电 5月21日，青海省西宁市湟中区首届中(藏)医药康养文化推广活动在湟中区中医院启幕，让传统医药文化可感、可触、可享。此前，《中华医藏·藏医药卷》成果发布会在北京举行。作为河湟文化核心发源地，湟中区中(藏)医药传承历史悠久、民众根基深厚。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-21/doc-inhyshrf6355481.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-21/doc-inhyshrf6355481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637383065","title":"5月21日司太立跌6.25%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637383065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637383065?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:28","pubTimestamp":1779352119,"startTime":"0","endTime":"0","summary":"证券之星消息，5月21日司太立跌6.25%，收盘报12.89元，换手率14.24%，成交量62.42万手，成交额8.31亿元。重仓司太立的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为14.08。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.46亿元，最新净值0.5976，较上一交易日下跌0.83%，近一年上涨14.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","159938","BK0239","BK1161","603520","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806569","title":"创新药迎政策利好 富国港股通医药优选即将结束募集","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806569","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637806569?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:58","pubTimestamp":1779335880,"startTime":"0","endTime":"0","summary":"近期，中国创新药出海再添重磅利好，恒瑞医药与BMS达成总金额约152亿美元的全球战略合作，标志着国内创新药从“出海授权”迈入“全球共创”新周期；与此同时，港版FDA计划于年底成立，内地医保目录调整同步提速，创新药产业迎来多重利好。在此背景下，富国港股通医药优选混合型证券投资基金正在发行中，并将于5月22日结束募集。该基金专注港股医药赛道，为投资者布局港股创新药龙头提供便捷通道。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-21/doc-inhyrrtp6358211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","VXUS","159992","09939","BK1161","06978","BK4588","159938","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637879691","title":"创胜集团医药-B(06628)合作伙伴INHIBRX报告OZEKIBART的CRC最新积极数据并宣布就治疗软骨肉瘤提交美国BLA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637879691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637879691?lang=zh_cn&edition=full","pubTime":"2026-05-21 06:25","pubTimestamp":1779315934,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 发布公告，其合作伙伴Inhibrx Biosciences, Inc. 近期报告了其评估ozekibart 联合FOLFIRI用于局部晚期或转移性、不可切除结直肠癌患者的1/2期研究的积极更新中期数据。除CRC适应症外，Inhibrx宣布ozekibart于软骨肉瘤方面取得一项重要监管里程碑。于2026年4月，Inhibrx已向FDA提交ozekibart用于常规软骨肉瘤的BLA，而该疾病目前尚无获批准的系统性治疗选项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4213","BK1574","LU0456854461.SGD","09939","159938","CRC","06628","BK1515","LU0266512127.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636484566","title":"森萱医药（920946）披露2025年年度权益分派实施公告，5月20日股价下跌1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636484566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636484566?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:22","pubTimestamp":1779272539,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，森萱医药报收于9.95元，较前一交易日下跌1.87%，最新总市值为42.48亿元。该股当日开盘10.19元，最高10.22元，最低9.92元，成交额达2044.6万元，换手率为0.48%。森萱医药近日披露《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案已获2026年5月18日股东会审议通过。本次权益分派以公司现有总股本426,918,340股为基数，向全体股东每10股派1.6元人民币现金，共计派发现金红利68,306,934.40元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636122758","title":"脑机接口尚处早期 AD药效待突破！下一个医药爆款在何处？","url":"https://stock-news.laohu8.com/highlight/detail?id=2636122758","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636122758?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:28","pubTimestamp":1779265680,"startTime":"0","endTime":"0","summary":"【脑机接口尚处早期 AD药效待突破！下一个医药爆款在何处？】2025年，A股医药板块上市公司交出的成绩单不可谓不亮眼。然而，与扎实的业绩基本面形成鲜明对比的，是相关公司股价的“温吞”表现。这一“叫好不叫座”的现象，成为近期产业与投资界热议的焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743503958.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743503958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","AD","159938","BK1515","BK1574","09939","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636581259","title":"5月20日热景生物跌9.64%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636581259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636581259?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:26","pubTimestamp":1779265601,"startTime":"0","endTime":"0","summary":"证券之星消息，5月20日热景生物跌9.64%创60日新低，收盘报83.85元，换手率4.92%，成交量4.57万手，成交额3.78亿元。重仓热景生物的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共24家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。该公募基金现任基金经理为赵伟 王超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000029434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1574","BK1161","BK1515","BK0239","688068"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636892567","title":"劲方医药-B午前涨近5% 西南证券首次覆盖建议积极关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892567","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636892567?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:23","pubTimestamp":1779247380,"startTime":"0","endTime":"0","summary":"　　劲方医药-B盘中涨超6%，截至发稿，股价上涨4.62%，现报35.80港元，成交额1795.20万港元。　　CDE官网最新公示显示，劲方医药申报的GFS202A注射液临床试验申请，已于5月12日正式获得受理，受理号为CXSL2600491。　　西南证券发布研报称，公司以产品矩阵进军胰腺癌、非小细胞肺癌、恶病质等大适应症市场，力求覆盖 1L 及各线治疗，产品进度全球领先；预计 2026-2028 年收入分别为 0.85/1.02/3.11亿元，分别同比-35%/+20%/+205%，首次覆盖，建议积极关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-20/doc-inhyphnm9433137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK0012","159938","BK0276","BK1515","02595","BK0183","BK1161","BK0188","BK0028","BK1574","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894070","title":"港股异动 | 劲方医药-B(02595)午前涨超6% GDF15/IL-6双抗注射液获CDE临床受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894070","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636894070?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:16","pubTimestamp":1779246963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B午前涨超6%，截至发稿，涨5.08%，报35.96港元，成交额1681.63万港元。消息面上，CDE官网最新公示显示，劲方医药申报的GFS202A注射液临床试验申请，已于5月12日正式获得受理，受理号为CXSL2600491。公开资料显示，GFS202A为全球首款靶向GDF15与IL-6的双特异性抗体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CDE","BK4017","LU1223082519.USD","BK4588","LU1223082196.USD","BK1515","BK4585","LU1223083913.SGD","BK1574","VXUS","09939","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636896784","title":"深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2636896784","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636896784?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:22","pubTimestamp":1779240142,"startTime":"0","endTime":"0","summary":"截至5月19日收盘，市场探底回升，沪指、深成指先后翻红。医药ETF（512120）收平，港股通生物科技ETF（159102）上涨0.27%。相关个股中，恒瑞医药下跌1.6%、药明合联上涨3.28%、科伦博泰生物上涨1.27%、万泰生物下跌1.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203742884813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203742884813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU2580892789.USD","LU1255011170.USD","LU1820825898.SGD","LU0359201885.HKD","BK1191","LU0405327494.USD","LU1997244956.HKD","LU1997245177.USD","LU2097828631.EUR","LU0359202008.SGD","BK1574","159938","01276","LU1146622755.USD","BK1515","LU1064131003.USD","LU1328615791.USD","LU1023057109.AUD","BK0188","LU1969619763.USD","LU2580892862.HKD","LU2148510915.USD","LU1580142542.USD","LU1997245094.SGD","LU2488822045.USD","LU2097828474.EUR","BK0060","BK0183","LU2097828805.USD","LU1064130708.USD","BK0239","LU2495084118.USD","BK0028","LU0405327148.USD","LU0359201612.USD","LU2328871848.SGD","LU2289578879.USD","BK0196","600276","LU2097828557.USD","LU2097828714.EUR","LU1781817850.SGD","LU1655091616.SGD","BK0012","09939","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856028","title":"“果蔬第一股”跨界医药：宏辉果蔬7亿收购施美药业，实控人医药背景与资金压力受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856028","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636856028?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:24","pubTimestamp":1779193491,"startTime":"0","endTime":"0","summary":"这意味着，宏辉果蔬此前抛出的跨界医药收购，正在进入实施层面。据公告，宏辉果蔬拟使用自有及自筹资金7.00052亿元，受让自然人江鸿持有的施美药业41.128%股份。这也使得外界将宏辉果蔬此次跨界医药，与新实控人体系的医药产业背景联系起来。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779183138104034997","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK0238","159938","BK1515","BK1574","09939","603336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636832997","title":"星昊医药（920017）披露2025年年度股东会决议公告，5月19日股价上涨1.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636832997","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636832997?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:51","pubTimestamp":1779184276,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，星昊医药报收于17.45元，较前一交易日上涨1.63%，最新总市值为21.78亿元。该股当日开盘17.25元，最高17.5元，最低17.23元，成交额达2238.79万元，换手率为1.04%。近日，星昊医药披露《2025年年度股东会决议公告》。所有议案均获全票通过，出席股东持有表决权股份占公司总股本的43.8067%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","09939","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636116025","title":"5月18日奥赛康跌5.12%，永赢医药创新智选混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636116025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636116025?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:33","pubTimestamp":1779093200,"startTime":"0","endTime":"0","summary":"证券之星消息，5月18日奥赛康跌5.12%，收盘报15.93元，换手率1.57%，成交量14.61万手，成交额2.35亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为永赢基金的永赢医药创新智选混合发起A。永赢医药创新智选混合发起A目前规模为11.25亿元，最新净值1.6026，较上一交易日下跌1.2%，近一年上涨29.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800023153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","159938","09939","BK1161","002755","BK1574","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046305","title":"港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046305?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:38","pubTimestamp":1779075485,"startTime":"0","endTime":"0","summary":"消息面上，霍尔木兹海峡持续封锁，正推动油价攀升至每桶105美元以上。全球债券市场抛售潮征兆已现。美国10年期国债收益率升至4.5%以上，日本30年期国债收益率首次突破4%，英国长期国债收益率则升至28年来的最高水平，引发市场对于未来全球金融环境趋紧的担忧。其中，4 月全球、美国、国内创新药投融资均呈现强劲复苏的态势。但也有分析人士指出，若全球利率环境进入更高水平且持续，将冲击创新药行业估值及融资端。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1574","BK4585","BK4588","BK1585","02137","09141","09939","VXUS","BK1587","09966","06978","02171","03141","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636468070","title":"奥克股份：公司聚乙二醇产品主要应用于医药原料药、锂电新能源及日化等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2636468070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636468070?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:33","pubTimestamp":1779075208,"startTime":"0","endTime":"0","summary":"证券之星消息，奥克股份(300082)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：在芯片制造的后端（BEOL）互连工艺中填充铜需要聚乙二醇基材料充当抑制剂，据闻国内芯片公司都采购国外电子级聚乙二醇，请问公司作为聚乙二醇龙头还没做到此项进口替代吗？奥克股份回复：尊敬的投资者，您好！公司聚乙二醇产品主要应用于医药原料药、锂电新能源及日化等领域。公司密切关注聚乙二醇在新兴应用领域的发展动态。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800012568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","300082","159875","BK0070","BK0155","BK1161","000941.SH","160640","BK0201","BK1515","BK0028","BK1574","BK0229","399941"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","LU0348784397.USD","BK1191","BK1141","LU1794554557.SGD","BK1593","02162","IE00BPRC5H50.USD","LU0540923850.HKD","159938","09926","LU2399975544.HKD","LU0348825331.USD","LU0417516738.SGD","BK1583","LU0348735423.USD","LU0348767384.USD","LU0348827113.USD","BK1574","LU1961090484.USD","LU0634319403.HKD","LU0348783233.USD","LU0561508036.HKD","LU2476274308.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","IE00B5MMRT66.SGD","LU0348766576.USD","00460","09995","LU2778985437.USD","LU0417516902.SGD","LU2476274720.SGD","09939","BK1515","02268","BK1600","06855","IE00B543WZ88.USD","LU1720050803.USD","LU2488822045.USD","BK1587","02410","06978","01672","LU0417516571.SGD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0868},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0295},{"period":"6month","weight":0.3418},{"period":"1year","weight":0.8392},{"period":"ytd","weight":0.3418}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.0876},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.025967},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}